Jan 27 2010
Idaho Technology, Inc. (ITI) announced today that clinical trials of the 
      FilmArray Respiratory Panel (RP) have commenced at three US Hospital 
      Laboratories.
    
“For this study, we will be testing nasopharyngeal swab specimens from 
      1,000 patients and comparing the results from the FilmArray Respiratory 
      Panel to the results from conventional as well as other molecular 
      diagnostic technologies”
    
      “We believe that the FilmArray RP holds tremendous potential for 
      hospital clinical laboratories frustrated with the hassle, long 
      turnaround times, and inferior sensitivity and specificity of viral 
      culture, DFA, and rapid flu tests. The FilmArray RP is a powerful 
      molecular diagnostic assay designed for comprehensive detection of 
      common respiratory pathogens and yet is still incredibly simple and easy 
      to use,” said Kirk Ririe, CEO of Idaho Technology. “Beginning these 
      clinical trials represents a significant milestone in the development of 
      the FilmArray which we anticipate will soon become ITI’s flagship 
      technology,” Ririe added.
    
    
      The much anticipated FilmArray RP is a user-friendly multiplex PCR 
      platform capable of detecting 21 common respiratory viruses and 
      bacteria. The FilmArray RP includes integrated sample preparation, 
      requires only 5 minutes of hands-on time, and reports results in less 
      than an hour.
    
    
      “For this study, we will be testing nasopharyngeal swab specimens from 
      1,000 patients and comparing the results from the FilmArray Respiratory 
      Panel to the results from conventional as well as other molecular 
      diagnostic technologies,” commented Beth Lingenfelter, director of 
      regulatory affairs. “Following data collection and analysis, we intend 
      to submit a 510k application to the FDA for use of the FilmArray RP as 
      an In Vitro Diagnostic product for patients with symptoms of upper 
      respiratory tract infection.”
    
    
      The clinical trials will be conducted at Children’s Medical Center, in 
      association with UT Southwestern Medical Center, Dallas TX; Detroit 
      Medical Center, Detroit, MI; and The Medical University of South 
      Carolina, Charleston, SC.